Publication date: Oct 17, 2019
Dr Teresa Amaral speaks to ecancer at ESMO 2019 in Barcelona about melanoma studies that stood out at the conference.
Dr Amaral begins by talking about research in the neoadjuvant setting, including the 2-year follow-up results of a large phase II trial looking at TVEC in neoadjuvant treatment versus surgery alone in patients with resectable stage IIIBO-IVM1a melanoma and two Dutch trials that were presented investigating the combination of ipilimumab and nivolumab. She also comments on the biomarker study analysis being presented at the conference with regards to immunotherapy.
In the metastatic and adjuvant setting, she comments on the 3-year efficacy and biomarker results from the CheckMate 238 trial, discusses what the IMMUNED study results meant for the recommended duration of combined immunotherapy and talks about what can be understood from the 5-year update results from the CheckMate 067 trial.
Dr Amaral also explains why the data presented on the ABC trial – which is an update on the combination of nivolumab and ipilimumab versus nivolumab alone in patients with asymptomatic melanoma brain metastases – indicates that it is important to provide this combination in the first-line setting.
To conclude, Dr Amaral summarises many of the reoccurring aspects of the above studies, and suggests what clinicians can take away from the highlights of this meeting.
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Melanoma |
| disease | DOID | Melanoma |
| pathway | BSID | Melanoma |
| gene | UNIPROT | LARGE1 |
| drug | DRUGBANK | Ipilimumab |
| drug | DRUGBANK | Nivolumab |
| drug | DRUGBANK | Abacavir |
| disease | MESH | metastases |
Similar
- IPI plus NIVO shows efficacy in resected stage IV melanoma
- OpACIn-neo trial RFS and biomarker analyses: optimal neoadjuvant ipi/nivo dosing in melanoma